Clinical Trial Detail

NCT ID NCT02093403
Title Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ramiro Garzon
Indications

acute myeloid leukemia

Therapies

Decitabine + Selinexor

Age Groups: adult

No variant requirements are available.